BDX · 10-Q · 2026Q2 · Full report
Acquisition / Partnership / Divestiture
BECTON DICKINSON & CO · 2026-08-06 · Importance 71 · Surprise 60 · In source text
On February 9, 2026, BD completed the spin-off of its former Biosciences and Diagnostic Solutions business and its combination with Waters Corporation in a Reverse Morris Trust transaction. The former Life Sciences business is presented as discontinued operations, and BD reorganized its continuing operations into Medical Essentials, Connected Care, BioPharma Systems and Interventional. BD received a $4 billion cash distribution in connection with the transaction, which it used to fund second-quarter share repurchases and debt repayments, while continuing to pursue strategic tuck-in acquisitions and geographic expansion.
Key facts
- On February 9, 2026, BD completed the spin-off of its former Biosciences and Diagnostic Solutions business and the combination of the business with Waters Corporation in a Reverse Morris Trust transaction. source
- As a result of the CareFusion acquisition, BD’s U.S. infusion pump business is operating under a Consent Decree with the FDA. source
- The Consent Decree authorizes the FDA to order BD’s U.S. infusion pump business to cease manufacturing and distributing products, recall products or take other actions, and order the payment of significant monetary damages if the business fails to comply with any provision of the Consent Decree. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | negative | realized | — | On February 9, 2026, BD completed the spin-off of its former Biosciences and Diagnostic Solutions business and the combination of the… |
| revenue | negative | contingent | — | The Consent Decree authorizes the FDA to order BD’s U.S. infusion pump business to cease manufacturing and distributing products, recall… |